BioCentury
ARTICLE | Finance

Fewer, further

AmorChem plans to fund portfolio companies for longer with second fund

December 15, 2017 12:58 AM UTC

AmorChem hopes to garner higher returns with its second early stage life sciences fund by financing fewer projects further into development.

The Montreal VC raised C$44.2 million (US$34.4 million) toward a planned C$50 million (US$38.9 million) fund that will invest in 12-15 biotechs emerging from Quebec universities and research centers. The final close is expected next year...